SCHEMBL1072174

SCHEMBL1072174

Cc1ccccc1N(C)N=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
LMNA P02545 3/20 0.42
ALOX15 P16050 3/20 0.42
MEN1 O00255 2/20 0.42
RGS12 O14924 2/20 0.42
USP2 O75604 2/20 0.42
POLB P06746 2/20 0.42
THRB P10828 2/20 0.42
PKM P14618 2/20 0.42
HPGD P15428 2/20 0.42
NFKB1 P19838 2/20 0.42
APEX1 P27695 2/20 0.42
BRCA1 P38398 2/20 0.42
RECQL P46063 2/20 0.42
BLM P54132 2/20 0.42
GNAI1 P63096 2/20 0.42
KMT2A Q03164 2/20 0.42
HIF1A Q16665 2/20 0.42
HSD17B10 Q99714 2/20 0.42
TDP1 Q9NUW8 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29728715 1.00 ALDH1A1 (0.42) ALDH1A1LMNAALOX15MEN1RGS12
SCHEMBL4146720 0.85 ALDH1A1 (0.48) ALDH1A1LMNAALOX15MEN1RGS12
SCHEMBL3690501 0.79 ALDH1A1 (0.46) ALDH1A1LMNAALOX15BLMMAPT
SCHEMBL7721860 0.79 TSHR (0.41) ALDH1A1LMNAALOX15BLMMAPT
SCHEMBL14873544 0.77 SIGMAR1 (0.42) ALDH1A1LMNAMAPTSIGMAR1TSHR
SCHEMBL673129 0.76 ALDH1A1 (0.41) ALDH1A1LMNAALOX15MEN1RGS12
SCHEMBL3724687 0.76 SIGMAR1 (0.41) ALDH1A1LMNABLMMAPTCYP1A2
SCHEMBL28347773 0.76 ALDH1A1 (0.41) ALDH1A1LMNAALOX15MEN1RGS12
SCHEMBL9549156 0.73 TSHR (0.45) ALDH1A1LMNAMAPTSIGMAR1TSHR
SCHEMBL9877100 0.72 ALDH1A1 (0.39) ALDH1A1LMNAALOX15MEN1RGS12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7539006-B2 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2009-05-26 US claimed
CN-100456398-C Electrolyte for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORP (JP) 2009-01-28 CN claimed
US-20070029529-A1 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor KOMATSU AKIHIKO 2007-02-08 US claimed
US-20040245105-A1 Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2004-12-09 US claimed
CN-1529892-A Electrolyte for driving electrolytic capacitor and electrolytic capacitor 如碧空株式会社 2004-09-15 CN claimed
EP-1437749-A1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR Rubycon Corporation (JP) 2004-07-14 EP claimed
CN-115255358-B Surface modification method of metal powder material, modified metal powder material and application of modified metal powder material 西安隆基乐叶光伏科技有限公司 2024-01-16 CN disclosed
US-11833204-B2 Visible light-activatable nanoparticles for cancer immunotherapy and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-12-05 US disclosed
CN-114752955-B Method for electrochemically synthesizing N-nitroso-2-aminobenzophenone compound 广西师范大学 2023-06-16 CN disclosed
US-20220370611-A1 VISIBLE LIGHT-ACTIVATABLE NANOPARTICLES FOR CANCER IMMUNOTHERAPY AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-11-24 US disclosed
CN-115255358-A Surface modification method of metal powder material, modified metal powder material and application thereof 西安隆基乐叶光伏科技有限公司 2022-11-01 CN disclosed
CN-114752955-A Method for electrochemically synthesizing N-nitroso-2-aminobenzophenone compound 广西师范大学 2022-07-15 CN disclosed
EP-1460660-B1 ELECTROLYTIC CAPACITOR AND ELECTROLYTIC SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR RUBYCON CORP (JP) 2013-04-10 EP disclosed
CN-1494723-A Electrolytic capacitor and electrolyte for driving electrolytic capacitor 如碧空株式会社 2004-05-05 CN disclosed
EP-1243268-A1 MEDICINAL COMPOSITION Nippon Shinyaku Co., Ltd. (JP) 2002-09-25 EP disclosed
EP-1156045-A1 AMIDE DERIVATIVES AND DRUG COMPOSITIONS Nippon Shinyaku Co., Ltd. (JP) 2001-11-21 EP disclosed
US-4335245-A REACTION OF A HYDROXYPYRIDONE WITH P-NITROSODIMETHYLANILINE FOLLOWED BY HYDROLYSIS CIBA-GEIGY AG (CH) 1982-06-15 US disclosed
US-4288598-A DYE-BLEACH CATALYSTS CIBA-GEIGY AG (CH) 1981-09-08 US disclosed
US-4244843-A IMPROVED WEATHERPROOFING PROPERTIES BY HOMOGENEOUS CROSSLINKING OF DIENE-ETHYLENE-PROPYLENE TERPOLYMER BLEND MITSUBISHI BELTING, LTD. (JP) 1981-01-13 US disclosed
US-4209596-A Two step process for producing vulcanized rubber MITSUBOSHI BELTING, LTD. (JP) 1980-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11833204-B2 Visible light-activatable nanoparticles for cancer immunotherapy and use thereof CD47, PDCD1, TP53 ALDH1A1 3091/4885LMNA 3175/4885ALOX15 2492/4885
US-20220370611-A1 VISIBLE LIGHT-ACTIVATABLE NANOPARTICLES FOR CANCER IMMUNOTHERAPY AND USE THEREOF CD47, PDCD1, TP53 ALDH1A1 3091/4885LMNA 3175/4885ALOX15 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.